All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
The plant will have installed production capacity of 3,120 MT/month
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
